- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05965180
Interstitiell bedömning av arkitektonisk heterogenitet i prostatacancer med hjälp av en finnål fotoakustisk sond
In this project, we will integrate the Photoacoustic (PA) technology into a prostate biopsy procedure through a fine needle probe. The needle probe will be in the shape of a biopsy needle and compatible with the needle insertion mechanism in the transrectal ultrasound (TRUS) probe. When inserted into the prostate, the fine needle PA probe will assess the histological information in its surrounding tissue without any tissue extraction. The needle probe has been tested in prostate tissue samples and whole human prostates ex vivo.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
14AUG2024- enrollment was increased to 50 subjects
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Cancer AnswerLine
- Telefonnummer: 1-800-865-1125
- E-post: CancerAnswerLine@med.umich.edu
Studieorter
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Rekrytering
- University of Michigan Rogel Cancer Center
-
Kontakt:
- Cancer AnswerLine
- Telefonnummer: 800-865-1125
- E-post: CancerAnswerLine@med.umich.edu
-
Huvudutredare:
- Guan Xu, Phd
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients with planned prostate biopsy procedures will be recruited through U-M Urology Clinics
Beskrivning
Inclusion Criteria:
- 1) Planned prostate biopsy as part of routine clinical care
- 2) > 40 and <80 years old
Exclusion Criteria:
- 1) Known history of bleeding disorders or
- 2) Patients taking anticoagulants, no matter doses or washout time
- 3) Known allergy to silicone material
- 4) Unable to provide informed consent
- 5) Either the surgeon or the patient do not think the patient will not be able to complete all parts of the study, the patient will be excluded
- 6) Involved in other investigational studies.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: OTHER
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Biopsy
Patients will be identified once prostate biopsies have been scheduled. Once enrolled on trial, patients will undergo standard biopsy procedure as per clinical care. During this biopsy, research measurements will be completed using the fine needle photoacoustic probe. |
Fine Needle Photoacoustic Probe guided by the standard biopsy system without tissue core extraction |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Demonstration of reliable measurements
Tidsram: day 1
|
The primary aim of this study is to demonstrate that our fine needle PA probe can acquire reliable measurements of prostate glands. This will be indicated by a signal-to-noise ratio of the measurements that is larger than one. We will calculate the signal to noise ratio of the signals as the peak-to-peak signal magnitude over the amplitude of the system background signal. The technical failure is that we will not be able to achieve measurements with signal-to-noise ratios larger than 1 in 10% of the measurements. We will have a futility analysis after first 5 patients are completed (thus 10 measurements). If of those 10 measurements, 2 have a SNR less 1, then the study will be stopped as it is unlikely to meet its 90% target. |
day 1
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Determining the ability to observe differences between benign and cancerous regions
Tidsram: day 1
|
The secondary aim of this study is documenting our ability to observe differences between the PASA linear slope values derived from benign and cancerous regions, i.e., to detect the difference of 0.05 of 0.19, 0.17, 0.14, 0.20 dB/MHz between the means of the linear slopes in benign and cancerous regions at the wavelengths of 1220 nm, 1370 nm, 800 nm and 266 nm, respectively. We will aim at differentiating the measurements in benign and cancerous regions at specific wavelengths. We have a null hypothesis for each wavelength that at this specific wavelength, our measurement cannot differentiate the benign and cancerous regions. We will test the hypothesis with paired t-tests. |
day 1
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Guan Xu, Phd, University of Michigan
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- UMCC 2022.015
- HUM00217834 (Annan identifierare: University of Michigan)
- R37CA222829 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .